Skip to content

INSYTE with SurePlanTM LiverY90

INSYTE with SurePlanTM Liver Y90

Insyte

Collaboration between Sirtex Medical and MIM Software Inc. advances innovation and increases precision of liver-directed oncology therapies for patients.

SurePlan

Key Features

 

Inyte Logo

insyte

mim


MIM Software Inc. is the legal manufacturer of the SurePlan LiverY90 Software.
SurePlan is a trademark of MIM Software Inc.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician Indications for Use: SIR-Spheres® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child Pugh-A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Side Effects: Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, acute cholecystitis and radioembolization induced liver disease (REILD). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.